Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Biperiden Hydrochloride (KL 373 Hydrochloride) is an antiparkinsonian agent, which is the selective central M1 cholinoreceptors blocker and it is used for the adjunctive treatment of all forms of Parkinson's disease (postencephalitic, idiopathic, and arteriosclerotic)[1]. Target: M1 receptors Biperiden is an antiparkinsonian agent of the anticholinergic type. Biperiden has an atropine-like blocking effect on all peripheral structures which are parasympathetic-innervate and it also has a prominent central blocking effect on M1 receptors[2]. Biperiden (0.11 mg/kg), benactyzine (0.3 mg/kg),caramiphen (10 mg/kg), procyclidine (3 mg/kg), and trihexyphenidyl (0.12 mg/kg) separately and each in combination with physostigmine (0.1 mg/kg) is to make a comparative assessment of potential cognitive effects. The results showed that benactyzine, caramiphen, and trihexyphenidyl reduced rats' innate preference for novelty. Whereas biperiden and procyclidine did not [3]. Clinical indications: parkinsonism FDA Approved Date: Toxicity: Drowsiness; vertigo; headache; dizziness
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
10 mg | 35 days | $ 385.00 | |
50 mg | 35 days | $ 1,640.00 |
Description | Biperiden Hydrochloride (KL 373 Hydrochloride) is an antiparkinsonian agent, which is the selective central M1 cholinoreceptors blocker and it is used for the adjunctive treatment of all forms of Parkinson's disease (postencephalitic, idiopathic, and arteriosclerotic)[1]. Target: M1 receptors Biperiden is an antiparkinsonian agent of the anticholinergic type. Biperiden has an atropine-like blocking effect on all peripheral structures which are parasympathetic-innervate and it also has a prominent central blocking effect on M1 receptors[2]. Biperiden (0.11 mg/kg), benactyzine (0.3 mg/kg),caramiphen (10 mg/kg), procyclidine (3 mg/kg), and trihexyphenidyl (0.12 mg/kg) separately and each in combination with physostigmine (0.1 mg/kg) is to make a comparative assessment of potential cognitive effects. The results showed that benactyzine, caramiphen, and trihexyphenidyl reduced rats' innate preference for novelty. Whereas biperiden and procyclidine did not [3]. Clinical indications: parkinsonism FDA Approved Date: Toxicity: Drowsiness; vertigo; headache; dizziness |
Synonyms | KL 373 (Hydrochloride) |
Molecular Weight | 347.92 |
Formula | C21H30ClNO |
CAS No. | 1235-82-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: 5 mg/mL (14.37 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Biperiden Hydrochloride 1235-82-1 Others KL 373 KL-373 KL373 KL 373 (Hydrochloride) inhibitor inhibit